Optos and Toku Collaborate to Integrate AI-Powered BioAge into U.S. Eye Care Practices
Optos has entered a new partnership with Toku to bring BioAge, an AI-driven health assessment tool, to eye care professionals across the United States. This collaboration will enable the integration of BioAge into Optos devices, enhancing the role of retinal imaging in systemic health evaluation.
AI-Driven Biological Age Assessment via Retinal Imaging
Toku’s BioAge technology utilizes artificial intelligence to estimate a patient’s biological age by analyzing vascular and metabolic biomarkers visible in the retina. Unlike traditional eye exams, this tool offers a broader health snapshot, providing insight into cardiovascular and metabolic wellness through ultra-widefield retinal imaging.
According to Optos, a single pair of ultra-widefield retinal images is sufficient to generate this systemic health insight, offering actionable information for patients that goes beyond ocular conditions.
BioAge Compatibility with Existing Optos Devices
The collaboration allows BioAge to be deployed across existing Optos platforms, including the Daytona, Monaco, Monaco Pro, and California devices, without the need for hardware replacement.
“We are delighted to offer our customers the ability to seamlessly integrate BioAge into their workflow,” said Masayuki Numako, Director & Executive Vice President, Head of Healthcare Business Division at Optos. “This collaboration allows eye care professionals to deliver greater value to their patients through a deeper understanding of overall wellness.”
“Our mission is to empower individuals with health insights that encourage proactive care and healthier lifestyles,” added Ehsan Vaghefi, CEO of Toku. “Through this agreement with Optos, we are excited to make BioAge accessible to more than 20,000 eyecare practices across the United States equipped with ultra-widefield imaging devices.”
The integrated BioAge solution is scheduled to debut at Vision Expo West, taking place September 17–20 in Las Vegas.
